Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Flora Peyvandi

Showing results (451-460 of 500) with videos related to

Pageof 50
Sort By:
Blood|March 7, 2024
Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis: the ATLAS-PPX trialGili Kenet, Beatrice Nolan, Bulent Zulfikar, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|August 17, 2018
Rate and appropriateness of polypharmacy in older patients with hemophilia compared with age-matched controlsPier Mannuccio Mannucci, Alessandro Nobili, Emanuela Marchesini, et al.
Journal of Clinical Medicine|December 24, 2021
Real-World Rates of Bleeding, Factor VIII Use, and Quality of Life in Individuals with Severe Haemophilia A Receiving Prophylaxis in a Prospective, Noninterventional StudyGili Kenet, Yeu-Chin Chen, Gillian Lowe, et al.
Respiratory Research|October 10, 2020
COVID-19 multidisciplinary high dependency unit: the Milan modelStefano Aliberti, Francesco Amati, Maria Pappalettera, et al.
Blood|March 7, 2025
Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE studyGuy Young, Kaan Kavakli, Robert Klamroth, et al.
Blood|November 24, 2005
Combined deficiency of factor V and factor VIII is due to mutations in either LMAN1 or MCFD2Bin Zhang, Beth McGee, Jennifer S Yamaoka, et al.
BMC Medical Genomics|February 23, 2012
Identification of genetic risk variants for deep vein thrombosis by multiplexed next-generation sequencing of 186 hemostatic/pro-inflammatory genesLuca A Lotta, Mark Wang, Jin Yu, et al.
Journal of Infection and Public Health|January 23, 2024
Clinical characteristics and outcomes of vaccinated patients hospitalised with SARS-CoV-2 breakthrough infection: Multi-IPV, a multicentre study in Northern ItalyAndrea Lombardi, Simone Villa, Marta Colaneri, et al.
Blood Advances|August 8, 2022
Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studiesRebecca Kruse-Jarres, Flora Peyvandi, Johannes Oldenburg, et al.
Thrombosis and Haemostasis|September 21, 2018
Anti-ADAMTS13 Autoantibodies against Cryptic Epitopes in Immune-Mediated Thrombotic Thrombocytopenic PurpuraElien Roose, Gestur Vidarsson, Kadri Kangro, et al.
Pageof 50

Showing results (451-460 of 500) with videos related to

Sort By:
Pageof 50
Blood|March 7, 2024
Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis: the ATLAS-PPX trialGili Kenet, Beatrice Nolan, Bulent Zulfikar, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|August 17, 2018
Rate and appropriateness of polypharmacy in older patients with hemophilia compared with age-matched controlsPier Mannuccio Mannucci, Alessandro Nobili, Emanuela Marchesini, et al.
Journal of Clinical Medicine|December 24, 2021
Real-World Rates of Bleeding, Factor VIII Use, and Quality of Life in Individuals with Severe Haemophilia A Receiving Prophylaxis in a Prospective, Noninterventional StudyGili Kenet, Yeu-Chin Chen, Gillian Lowe, et al.
Respiratory Research|October 10, 2020
COVID-19 multidisciplinary high dependency unit: the Milan modelStefano Aliberti, Francesco Amati, Maria Pappalettera, et al.
Blood|March 7, 2025
Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE studyGuy Young, Kaan Kavakli, Robert Klamroth, et al.
Blood|November 24, 2005
Combined deficiency of factor V and factor VIII is due to mutations in either LMAN1 or MCFD2Bin Zhang, Beth McGee, Jennifer S Yamaoka, et al.
BMC Medical Genomics|February 23, 2012
Identification of genetic risk variants for deep vein thrombosis by multiplexed next-generation sequencing of 186 hemostatic/pro-inflammatory genesLuca A Lotta, Mark Wang, Jin Yu, et al.
Journal of Infection and Public Health|January 23, 2024
Clinical characteristics and outcomes of vaccinated patients hospitalised with SARS-CoV-2 breakthrough infection: Multi-IPV, a multicentre study in Northern ItalyAndrea Lombardi, Simone Villa, Marta Colaneri, et al.
Blood Advances|August 8, 2022
Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studiesRebecca Kruse-Jarres, Flora Peyvandi, Johannes Oldenburg, et al.
Thrombosis and Haemostasis|September 21, 2018
Anti-ADAMTS13 Autoantibodies against Cryptic Epitopes in Immune-Mediated Thrombotic Thrombocytopenic PurpuraElien Roose, Gestur Vidarsson, Kadri Kangro, et al.
Pageof 50